Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Long-Term Deferred Tax (2019 - 2025)

Historic Long-Term Deferred Tax for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $27.5 million.

  • Pharming's Long-Term Deferred Tax fell 2521.5% to $27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year decrease of 2521.5%. This contributed to the annual value of $30.5 million for FY2024, which is 263.1% up from last year.
  • According to the latest figures from Q3 2025, Pharming's Long-Term Deferred Tax is $27.5 million, which was down 2521.5% from $31.2 million recorded in Q2 2025.
  • Pharming's 5-year Long-Term Deferred Tax high stood at $39.0 million for Q2 2024, and its period low was $21187.0 during Q3 2022.
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $26.6 million (2023), whereas its average is $23.1 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first tumbled by 9990.13% in 2022, then soared by 12548644.45% in 2023.
  • Pharming's Long-Term Deferred Tax (Quarter) stood at $21414.0 in 2021, then soared by 107180.31% to $23.0 million in 2022, then grew by 29.55% to $29.8 million in 2023, then increased by 2.63% to $30.5 million in 2024, then decreased by 10.02% to $27.5 million in 2025.
  • Its last three reported values are $27.5 million in Q3 2025, $31.2 million for Q2 2025, and $18.4 million during Q1 2025.